Quibim and collaborators will share scientific advances at AACR22 on the use of radiomics in assessing treatment response of immunotherapy drugs
Amid spatial biology’s momentum, imaging is one of the key promising techniques for the visualization and treatment response assessment of novel immunotherapy drugs across different indications. Quibim team, led by the CEO, Dr. Angel Alberich-Bayarri, will be present in the upcoming congress of the American Association for Cancer Research (AACR) in New Orleans (April 8th – 13th) to showcase preliminary results on how radiomics can track the proliferation of immune infiltrates in lesions of patients with anti-PD1 refractory melanoma. There is a current lack of predictive biomarkers for immunotherapy in melanoma. Immunohistochemistry and gene sequencing are frequently assessed as part of translational research.
The results are part of a Phase II clinical study of a new molecule (BO-112) developed by Highlight Therapeutics S.L. (Valencia, ES), with the support of Merck (USA). A total of 15 hospitals from Spain and France have taken part in the study. The results presented at AACR show highly significant differences between the injected vs. non-injected lesions in specific radiomics features. Next steps will include the validation of these findings by assessing the correlation of radiomics with CD8+ T cells. This study might add insights on the use of imaging-based evaluation of immune infiltration in intratumoral immunotherapy and the creation of new ‘imaging biomarker panels’ that, in association with histologic and genetic markers can improve patient stratification and assessment of treatment response.
Here the details of the presentations:
|Apr 11, 2022 (9:00am)||CT107||Correlation of biomarkers and clinical benefit of intratumoral BO112 and pembrolizumab in patients with anti PD1 refractory melanoma||Beatriz García-Peláez, PhD|
|Apr 11, 2022 (9:00am)||CT109||Radiomic features in tumor assessment, preliminary results from a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with anti PD1 refractory melanoma||Ángel Alberich-Bayarri, PhD|
|April 12, 2022 (10:46-11:01am)||Hall B-C, Convention Center||Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: final results of SPOTLIGHT-203 phase 2 study||Iván Márquez-Rodas MD, PhD|